Avotermin (recombinant TGF-beta3) for Accelerated Wound Healing and Antiscarring
Cicatrix
Enrolment: 42 · Results not recorded
Loading the evidence…
Biologic · Biologic (recombinant human TGF-beta3, avotermin); not a discrete ChEMBL small molecule
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Cicatrix
Enrolment: 42 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Bilateral or unilateral vocal fold mucosal stripping injury under endoscopic guidance, with 2 cm oral mucosal and skin incision injuries for cross-tissue comparison
TGF-beta3 treatment reduced Emr1 transcription at 72 h, indicating less macrophage infiltration, and upregulated Fn1, Has1 and Has2. At 60 days the treated vocal fold mucosa had greater lamina propria cross-sectional area, less muscle fibre invasion, reduced Col3a1 transcription and collagen type I…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.